Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.44 |
| ▸ | ALKBH1 | Q13686 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5613881 | 0.87 | MAPT (0.43) | MAPTHPGDHTTPTGDR2KDM4E | |
| SCHEMBL5613851 | 0.81 | MAPT (0.52) | MAPTHPGDHTTALKBH2HPGDS | |
| SCHEMBL5614060 | 0.80 | KCNMA1 (0.41) | — | |
| SCHEMBL10202532 | 0.78 | EGLN1 (0.63) | ALKBH2HPGDSEGLN1ALKBH1 | |
| SCHEMBL5607411 | 0.75 | KMT2A (0.56) | MAPTKDM4EALDH1A1 | |
| SCHEMBL5606660 | 0.75 | KMT2A (0.40) | NPC1RAB9A | |
| SCHEMBL5613885 | 0.73 | NOTUM (0.44) | — | |
| SCHEMBL11480162 | 0.73 | ALKBH2 (0.63) | ALKBH2HPGDSEGLN1ALKBH1 | |
| SCHEMBL5613900 | 0.72 | SMN1; SMN2 (0.47) | HPGDKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL7546534 | 0.69 | CA1 (0.48) | MAPTTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838300-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | Emergent Product Development Gaithersburg Inc. (US) | 2007-10-03 | — | — | EP | claimed |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006071471-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2006-07-06 | — | — | WO | claimed |
| EP-1838300-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | Emergent Product Development Gaithersburg Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006071471-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | TYR, NFE2L2, CYP1A1 | MAPT 4105/4885HPGD 1451/4885HTT 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.